Abstract
In this article, we discuss the history of acute promyelocytic leukemia (APL) from the pre-therapeutic era, which began after its recognition by Hillestad in 1947 as a nosological entity, to the present day. It is a paradigmatic history that has transformed the “most malignant leukemia form” into the most curable one. The identification of a balanced reciprocal translocation between chromosomes 15 and 17, resulting in fusion between the promyelocytic leukemia gene and the retinoic acid receptor alpha, has been crucial in understanding the mechanisms of leukemogenesis, and responsible for the peculiar response to targeted therapy with all-trans retinoic acid (ATRA) and arsenic trioxide (ATO). We review the milestones that marked successive therapeutic advances, beginning with the introduction of the first successful chemotherapy in the early 1970s, followed by a subsequent incorporation of ATRA and ATO in the late 1980s and early 1990s which have revolutionized the treatment of this disease. Over the past two decades, treatment optimization has relied on the combination of ATRA, ATO, and chemotherapy according to risk-adapted approaches, which together with improvements in supportive therapy have paved the way for cure for most patients with APL.
Article PDF
Avoid common mistakes on your manuscript.
References
Bernard J. History of promyelocytic leukaemia. Leukemia 1994;8;S1–S5.
Pappenheim A. Uber die Wandlung des Lymphoïdozyten Begriffs und der Blatsmamm Zellen. Folia Haematol 1917;21;249–62.
Pittaluga G. Sur les caractères cytologiques du “promyélocyte” et sur le hiatus leucémien. Sang 1940;14;325–41.
Hillestad LK. Acute promyelocytic leukemia. Acta Med Scand 1957;159;189–94.
Bernard J, Weil M, Boiron M, Jacquillat C, Flandrin G, Gemon MF. Acute promyelocytic leukemia: results of treatment by daunorubicin. Blood 1973;41;489–96.
Caen JP, Mathé G, Xuan Chat L, Bernard J. Etude de la fibrinolyse au cours des hémopathies malignes. Transcripts of the Sixth Congress of the European Society of Hematology. Copenhagen: Karger; 1957, pp. 502–6.
Bernard J, Mathe G, Boulay J, Ceoard B, Chome J. [Acute promyelocytic leukemia: a study made on 20 cases]. Schweiz Med Wochenschr 1959;89;604–8 (in French).
Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol 1976;33;451–8.
Paietta E, Andersen J, Racevskis J, Gallagher R, Bennett J, Yunis J, et al. Significantly lower P-glycoprotein expression in acute promyelocytic leukemia than in other types of acute myeloid leukemia: immunological, molecular and functional analyses. Leukemia 1994;8;968–73.
Michieli M, Damiani D, Ermacora A, Geromin A, Michelutti A, Masolini P, et al. P-glycoprotein (PGP), lung resistance-related protein (LRP) and multidrug resistance-associated protein (MRP) expression in acute promyelocytic leukaemia. Br J Haematol 2000;108;703–9.
Takeshita A, Shinjo K, Naito K, Ohnishi K, Sugimoto Y, Yamakawa Y, et al. Role of P-glycoprotein in all-trans retinoic acid (ATRA) resistance in acute promyelocytic leukaemia cells: analysis of intracellular concentration of ATRA. Br J Haematol 2000;108;90–2.
Avvisati G, Petti MC, Lo-Coco F, Vegna ML, Amadori S, Baccarani M, et al. Induction therapy with idarubicin alone significantly influences event-free survival duration in patients with newly diagnosed hypergranular acute promyelocytic leukemia: final results of the GIMEMA randomized study LAP 0389 with 7 years of minimal follow-up. Blood 2002;100;3141–6.
Mandelli F, Labopin M, Granena A, Iriondo A, Prentice G, Bacigalupo A, et al. European survey of bone marrow transplantation in acute promyelocytic leukemia (M3). Working Party on Acute Leukemia of the European Cooperative Group for Bone Marrow Transplantation (EMBT). Bone Marrow Transplant 1994;14;293–8.
Sanz MA, Grimwade D, Tallman MS, Lowenberg B, Fenaux P, Estey EH, et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2009;113;1875–91.
Sanz MA, Fenaux P, Tallman MS, Estey EH, Löwenberg B, Naoe T, et al. Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet. Blood 2019;133;1630–43.
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Acute Myeloid Leukemia (Version 3.2021) – March 2, 2021, (n.d.). Available from: https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1411 (accessed April 7, 2021).
Sanz J, Montesinos P, Sanz MA. Role of hematopoietic stem cell transplantation in acute promyelocytic leukemia. Front Oncol 2021;11;614215.
Marty M, Ganem G, Fischer J, Flandrin G, Berger R, Schaison G, et al. [Acute promyelocytic leukemia: retrospective study of 119 patients treated with daunorubicin]. Nouv Rev Fr Hematol 1984;26;371–8 (in French).
Kantarjian HM, Keating MJ, Walters RS, Estey EH, McCredie KB, Smith TL, et al. Acute promyelocytic leukemia. M.D. Anderson Hospital experience. Am J Med 1986;80;789–97.
Golomb HM, Rowley J, Vardiman J, Baron J, Locker G, Krasnow S. Partial deletion of long arm of chromosome 17: a specific abnormality in acute promyelocytic leukemia?. Arch Intern Med 1976;136;825–8.
Rowley JD, Golomb HM, Dougherty C. 15/17 translocation, a consistent chromosomal change in acute promyelocytic leukaemia. Lancet 1977;309;549–50.
Rowley JD, Golomb HM, Vardiman J, Fukuhara S, Dougherty C, Potter D. Further evidence for a non-random chromosomal abnormality in acute promyelocytic leukemia. Int J Cancer 1977;20;869–72.
Fitzgerald PH, Fraser J, Beard MEJ. The geographical distribution of 15;17 translocation in acute promyelocytic leukemia. Cancer Genet Cytogenet 1981;3;273–4.
Teerenhovi L, Borgström GH, Mitelman F, Brandt L, Vuopio P, Timonen T, et al. Uneven geographical distribution of 15;17 translocation in acute promyelocytic leukaemia. Lancet 1978;312;797.
Larson RA, Kondo K, Vardiman JW, Butler AE, Golomb HM, Rowley JD. Evidence for a 15;17 translocation in every patient with acute promyelocytic leukemia. Am J Med 1984;76;827–41.
Grimwade D, Gorman P, Duprez E, Howe K, Langabeer S, Oliver F, et al. Characterization of cryptic rearrangements and variant translocations in acute promyelocytic leukemia. Blood 1997;90;4876–85.
Grimwade D, Biondi A, Mozziconacci MJ, Hagemeijer A, Berger R, Neat M, et al. Characterization of acute promyelocytic leukemia cases lacking the classic t(15;17): results of the European Working Party. Groupe Français de Cytogénétique Hématologique, Groupe de Français d’Hematologie Cellulaire, UK Cancer Cytogenetics Group and BIOMED 1 European Community-Concerted Action “Molecular Cytogenetic Diagnosis in Haematological Malignancies”. Blood 2000;96;1297–308.
Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, et al. A variant form of hypergranular promyelocytic leukaemia (M3). Br J Haematol 1980;44;169–70.
Mattei MG, Petkovich M, Mattei JF, Brand N, Chambon P. Mapping of the human retinoic acid receptor to the q21 band of chromosome 17. Hum Genet 1988;80;186–8.
de Thé H, Chomienne C, Lanotte M, Degos L, Dejean A. The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor α gene to a novel transcribed locus. Nature 1990;347;558–61.
Borrow J, Goddard AD, Sheer D, Solomon E. Molecular analysis of acute promyelocytic leukemia breakpoint cluster region on chromosome 17. Science 1990;249;1577–80.
Longo L, Pandolfi PP, Biondi A, Rambaldi A, Mencarelli A, Lo Coco F, et al. Rearrangements and aberrant expression of the retinoic acid receptor alpha gene in acute promyelocytic leukemias. J Exp Med 1990;172;1571–5.
de Thé H, Lavau C, Marchio A, Chomienne C, Degos L, Dejean A. The PML-RARα fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell 1991;66;675–84.
Kakizuka A, Miller WH, Umesono K, Warrell RP, Frankel SR, Murty VVVS, et al. Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RARα with a novel putative transcription factor, PML. Cell 1991;66;663–74.
Salomoni P, Pandolfi PP. The role of PML in tumor suppression. Cell 2002;108;165–70.
Lo Coco F, Diverio D, Avvisati G, Arcese W, Petti MC, Meloni G, et al. Molecular evaluation of residual disease as a predictor of relapse in acute promyelocytic leukaemia. Lancet 1992;340;1437–8.
Biondi A, Rambaldi A, Pandolfi PP, Rossi V, Giudici G, Alcalay M, et al. Molecular monitoring of the myl/retinoic acid receptor-alpha fusion gene in acute promyelocytic leukemia by polymerase chain reaction. Blood 1992;80;492–7.
Castaigne S, Balitrand N, de Thé H, Dejean A, Degos L, Chomienne C. A PML/retinoic acid receptor alpha fusion transcript is constantly detected by RNA-based polymerase chain reaction in acute promyelocytic leukemia. Blood 1992;79;3110–15.
Miller WH, Kakizuka A, Frankel SR, Warrell RP, DeBlasio A, Levine K, et al. Reverse transcription polymerase chain reaction for the rearranged retinoic acid receptor alpha clarifies diagnosis and detects minimal residual disease in acute promyelocytic leukemia. Proc Natl Acad Sci U S A 1992;89;2694–8.
Grimwade D, Howe K, Langabeer S, Burnett A, Goldstone A, Solomon E. Minimal residual disease detection in acute promyelocytic leukemia by reverse-transcriptase PCR: evaluation of PML-RAR alpha and RAR alpha-PML assessment in patients who ultimately relapse. Leukemia 1996;10;61–6.
Wang ZY, Chen Z. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood 2008;111;2505–15.
Degos L. The history of acute promyelocytic leukaemia. Br J Haematol 2003;122;539–53.
Pierce GB, Verney EL. An in vitro and in vivo study of differentiation in teratocarcinomas. Cancer 1961;14;1017–29.
Schubert D, Humphreys S, de Vitry F, Jacob F. Induced differentiation of a neuroblastoma. Dev Biol 1971;25;514–46.
Friend C, Scher W, Holland JG, Sato T. Hemoglobin synthesis in murine virus-induced leukemic cells in vitro: stimulation of erythroid differentiation by dimethyl sulfoxide. Proc Natl Acad Sci U S A 1971;68;378–82.
Sachs L. Control of normal cell differentiation and the phenotypic reversion of malignancy in myeloid leukaemia. Nature 1978;274;535–9.
Breitman TR, Selonick SE, Collins SJ. Induction of differentiation of the human promyelocytic leukemia cell line (HL-60) by retinoic acid. Proc Natl Acad Sci U S A 1980;77;2936–40.
Breitman TR, Collins SJ, Keene BR. Terminal differentiation of human promyelocytic leukemic cells in primary culture in response to retinoic acid. Blood 1981;57;1000–4.
Flynn PJ, Miller WJ, Weisdorf DJ, Arthur DC, Brunning R, Branda RF. Retinoic acid treatment of acute promyelocytic leukemia: in vitro and in vivo observations. Blood 1983;62;1211–17.
Nilsson B. Probable in vivo induction of differentiation by retinoic acid of promyelocytes in acute promyelocytic leukaemia. Br J Haematol 1984;57;365–71.
Daenen S, Vellenga E, van Dobbenburgh OA, Halie MR. Retinoic acid as antileukemic therapy in a patient with acute promyelocytic leukemia and Aspergillus pneumonia. Blood 1986;67;559–61.
Huang ME, Ye YC, Chen SR, Zhao JC, Gu LJ, Cai JR, et al. Alltrans retinoic acid with or without low dose cytosine arabinoside in acute promyelocytic leukemia. Report of 6 cases. Chin Med J (Engl) 1987;100;949–53.
Huang ME, Ye YC, Chen SR, Chai JR, Lu JX, Zhoa L, et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988;72;567–72.
Wang ZY, Sun GL, Lu JX, Gu LJ, Huang ME, Chen SR. Treatment of acute promyelocytic leukemia with all-trans retinoic acid in China. Nouv Rev Fr Hematol 1990;32;34–6.
Chen ZX, Xue YQ, Zhang R, Tao RF, Xia XM, Li C, et al. A clinical and experimental study on all-trans retinoic acid-treated acute promyelocytic leukemia patients. Blood 1991;78;1413–19.
Degos L, Chomienne C, Daniel MT, Berger R, Dombret H, Fenaux P, et al. Treatment of first relapse in acute promyelocytic leukaemia with all-trans retinoic acid. Lancet 1990;336;1440–1.
Castaigne S, Chomienne C, Daniel MT, Ballerini P, Berger R, Fenaux P, et al. All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results. Blood 1990;76;1704–9.
Warrell RP, Frankel SR, Miller WH, Scheinberg DA, Itri LM, Hittelman WN, et al. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N Engl J Med 1991;324;1385–93.
Fenaux P, Le Deley MC, Castaigne S, Archimbaud E, Chomienne C, Link H, et al. Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. European APL 91 Group. Blood 1993;82;3241–9.
Fenaux P, Castaigne S, Dombret H, Archimbaud E, Duarte M, Morel P, et al. All-transretinoic acid followed by intensive chemotherapy gives a high complete remission rate and may prolong remissions in newly diagnosed acute promyelocytic leukemia: a pilot study on 26 cases. Blood 1992;80;2176–81.
Sun G, Ouyang R, Chen S, Juang G, Zhang T. Follow-up of 481 patients with APL after CR using ATRA. Chin J Hematol 1994;15;411–15.
Warrell RP, Maslak P, Eardley A, Heller G, Miller WH, Frankel SR. Treatment of acute promyelocytic leukemia with all-trans retinoic acid: an update of the New York experience. Leukemia 1994;8;929–33.
Kanamaru A, Takemoto Y, Tanimoto M, Murakami H, Asou N, Kobayashi T, et al. All-trans retinoic acid for the treatment of newly diagnosed acute promyelocytic leukemia. Japan Adult Leukemia Study Group. Blood 1995;85;1202–6.
Fenaux P, Chastang C, Chomienne C, Degos L. Tretinoin with chemotherapy in newly diagnosed acute promyelocytic leukaemia. Lancet 1994;343;1033.
Fenaux P, Chevret S, Guerci A, Fegueux N, Dombret H, Thomas X, et al. Long-term follow-up confirms the benefit of all-trans retinoic acid in acute promyelocytic leukemia. Leukemia 2000;14;1371–7.
Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Ogden A, et al. All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med 1997;337;1021–8.
Frankel SR, Eardley A, Heller G, Berman E, Miller WH, Dmitrovsky E, et al. All-trans retinoic acid for acute promyelocytic leukemia: results of the New York Study. Ann Intern Med 1994;120;278–86.
Asou N, Adachi K, Tamura J, Kanamaru A, Kageyama S, Hiraoka A, et al. Analysis of prognostic factors in newly diagnosed acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Japan Adult Leukemia Study Group. J Clin Oncol 1998;16;78–85.
Fenaux P, Chastang C, Chevret S, Sanz M, Dombret H, Archimbaud E, et al. A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood 1999;94;1192–200.
Mandelli F, Diverio D, Avvisati G, Luciano A, Barbui T, Bernasconi C, et al. Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano-Malattie Ematologiche Maligne dell’Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative Groups. Blood 1997;90;1014–21.
Estey E, Thall PF, Pierce S, Kantarjian H, Keating M. Treatment of newly diagnosed acute promyelocytic leukemia without cytarabine. J Clin Oncol 1997;15;483–90.
Burnett AK, Grimwade D, Solomon E, Wheatley K, Goldstone AH. Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: result of the Randomized MRC Trial. Blood 1999;93;4131–43.
Sanz MA, Martín G, Rayón C, Esteve J, González M, Díaz-Mediavilla J, et al. A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARalpha-positive acute promyelocytic leukemia. PETHEMA group. Blood 1999;94;3015–21.
Lengfelder E, Reichert A, Schoch C, Haase D, Haferlach T, Löffler H, et al. Double induction strategy including high dose cytarabine in combination with all-trans retinoic acid: effects in patients with newly diagnosed acute promyelocytic leukemia. Leukemia 2000;14;1362–70.
Sanz MA, Martín G, González M, León A, Rayón C, Rivas C, et al. Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. Blood 2004;103;1237–43.
Sanz MA, Montesinos P, Vellenga E, Rayón C, de la Serna J, Parody R, et al. Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: long-term outcome of the LPA 99 multicenter study by the PETHEMA Group. Blood 2008;112;3130–4.
Sanz MA, Montesinos P, Rayón C, Holowiecka A, de la Serna J, Milone G, et al. Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome. Blood 2010;115;5137–46.
Lo-Coco F, Avvisati G, Vignetti M, Breccia M, Gallo E, Rambaldi A, et al. Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group. Blood 2010;116;3171–9.
Grimwade D, Jovanovic JV, Hills RK, Nugent EA, Patel Y, Flora R, et al. Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct preemptive arsenic trioxide therapy. J Clin Oncol 2009;27;3650–8.
Nagy L, Kao HY, Chakravarti D, Lin RJ, Hassig CA, Ayer DE, et al. Nuclear receptor repression mediated by a complex containing SMRT, mSin3A, and histone deacetylase. Cell 1997;89;373–80.
He LZ, Guidez F, Tribioli C, Peruzzi D, Ruthardt M, Zelent A, et al. Distinct interactions of PML-RARα and PLZF-RARα with co-repressors determine differential responses to RA in APL. Nat Genet 1998;18;126–35.
Grignani F, De Matteis S, Nervi C, Tomassoni L, Gelmetti V, Cioce M, et al. Fusion proteins of the retinoic acid receptor-α recruit histone deacetylase in promyelocytic leukaemia. Nature 1998;391;815–8.
Lin RJ, Evans RM. Acquisition of oncogenic potential by RAR chimeras in acute promyelocytic leukemia through formation of homodimers. Mol Cell 2000;5;821–30.
Pandolfi PP. Oncogenes and tumor suppressors in the molecular pathogenesis of acute promyelocytic leukemia. Hum Mol Genet 2001;10;769–75.
Lo-Coco F, Hasan SK. Understanding the molecular pathogenesis of acute promyelocytic leukemia. Best Pract Res Clin Haematol 2014;27;3–9.
Ablain J, de Thé H. Retinoic acid signaling in cancer: the parable of acute promyelocytic leukemia. Int J Cancer 2014;135;2262–72.
Minucci S, Nervi C, Lo Coco F, Pelicci PG. Histone deacetylases: a common molecular target for differentiation treatment of acute myeloid leukemias? Oncogene 2001;20;3110–15.
Martens JHA, Brinkman AB, Simmer F, Francoijs KJ, Nebbioso A, Ferrara F, et al. PML-RARα/RXR alters the epigenetic landscape in acute promyelocytic leukemia. Cancer Cell 2010;17;173–85.
Kamashev D, Vitoux D, de Thé H. PML-RARA-RXR oligomers mediate retinoid and rexinoid/cAMP cross-talk in acute promyelocytic leukemia cell differentiation. J Exp Med 2004;199;1163–74.
Zhu J, Gianni M, Kopf E, Honoré N, Chelbi-Alix M, Koken M, et al. Retinoic acid induces proteasome-dependent degradation of retinoic acid receptor α (RARα) and oncogenic RARα fusion proteins. Proc Natl Acad Sci U S A 1999;96;14807–12.
Freedman LP. Increasing the complexity of coactivation in nuclear receptor signaling. Cell 1999;97;5–8.
Lallemand-Breitenbach V, Jeanne M, Benhenda S, Nasr R, Lei M, Peres L, et al. Arsenic degrades PML or PML-RARα through a SUMO-triggered RNF4/ubiquitin-mediated pathway. Nat Cell Biol 2008;10;547–55.
Sahin U, de Thé H, Lallemand-Breitenbach V. PML nuclear bodies: assembly and oxidative stress-sensitive sumoylation. Nucleus 2014;5;499–507.
Montesinos P, Bergua JM, Vellenga E, Rayón C, Parody R, de la Serna J, et al. Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors. Blood 2009;113;775–83.
Muindi J, Frankel SR, Miller WH, Jakubowski A, Scheinberg DA, Young CW, et al. Continuous treatment with all-trans retinoic acid causes a progressive reduction in plasma drug concentrations: implications for relapse and retinoid “resistance” in patients with acute promyelocytic leukemia. Blood 1992;79;299–303.
Sun H, Ma L, Hu X, Zhang T. Treatment of acute promyelocytic leukemia by Ailing-1 therapy with use of syndrome differentiation of traditional Chinese medicine. Chin J Comb Trad Chin Med Western Med 1992;12;170–2.
Chen GQ, Shi XG, Tang W, Xiong SM, Zhu J, Cai X, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells. Blood 1997;89;3345–53.
Shen ZX, Chen GQ, Ni JH, Li XS, Xiong SM, Qiu QY, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997;89;3354–60.
Niu C, Yan H, Yu T, Sun HP, Liu JX, Li XS, et al. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood 1999;94;3315–24.
Soignet SL, Maslak P, Wang ZG, Jhanwar S, Calleja E, Dardashti LJ, et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 1998;339;1341–8.
Soignet SL, Frankel SR, Douer D, Tallman MS, Kantarjian H, Calleja E, et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 2001;19;3852–60.
Zhang P, Wang S, Hu L. Arsenic trioxide treated 72 cases of acute promyelocytic leukemia. Chin J Hematol 1996;17;58–62.
Shen ZX, Shi ZZ, Fang J, Gu BW, Li JM, Zhu YM, et al. All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci U S A 2004;101;5328–35.
Ghavamzadeh A, Alimoghaddam K, Ghaffari SH, Rostami S, Jahani M, Hosseini R, et al. Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapy. Ann Oncol 2006;17;131–4.
Mathews V, George B, Lakshmi KM, Viswabandya A, Bajel A, Balasubramanian P, et al. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity. Blood 2006;107;2627–32.
Estey E, Garcia-Manero G, Ferrajoli A, Faderl S, Verstovsek S, Jones D, et al. Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Blood 2006;107;3469–73.
Lo-Coco F, Avvisati G, Vignetti M, Thiede C, Orlando SM, Iacobelli S, et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med 2013;369;111–21.
Burnett AK, Russell NH, Hills RK, Bowen D, Kell J, Knapper S, et al. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial. Lancet Oncol 2015;16;1295–305.
Abaza Y, Kantarjian H, Garcia-Manero G, Estey E, Borthakur G, Jabbour E, et al. Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab. Blood 2017;129;1275–83.
Seftel MD, Barnett MJ, Couban S, Leber B, Storring J, Assaily W, et al. A Canadian consensus on the management of newly diagnosed and relapsed acute promyelocytic leukemia in adults. Curr Oncol 2014;21;234–50.
Chinese Society of Hematology, Chinese Medical Doctor Association; Chinese Medical Association. [Chinese guidelines for diagnosis and treatment of acute promyelocytic leukemia (2018)]. Zhonghua Xue Ye Xue Za Zhi 2018;39;179–83 (in Chinese).
Zhu HH, Hu J, Lo-Coco F, Jin J. The simpler, the better: oral arsenic for acute promyelocytic leukemia. Blood 2019;134;597–605.
Zhu HH, Wu DP, Jin J, Li JY, Ma J, Wang JX, et al. Oral tetraarsenic tetra-sulfide formula versus intravenous arsenic trioxide as first-line treatment of acute promyelocytic leukemia: a multicenter randomized controlled trial. J Clin Oncol 2013;31;4215–21.
Zhu HH, Wu DP, Du X, Zhang X, Liu L, Ma J, et al. Oral arsenic plus retinoic acid versus intravenous arsenic plus retinoic acid for non-high-risk acute promyelocytic leukaemia: a non-inferiority, randomised phase 3 trial. Lancet Oncol 2018;19;871–9.
Gill H, Yim R, Lee HKK, Mak V, Lin SY, Kho B, et al. Long-term outcome of relapsed acute promyelocytic leukemia treated with oral arsenic trioxide-based reinduction and maintenance regimens: a 15-year prospective study. Cancer 2018;124;2316–26.
Iland H, Reynolds J, Boddy A, Khoo L, Yuen S, Bryant C, et al. A comparative bioavailability study of encapsulated oral arsenic trioxide and intravenous arsenic trioxide in patients with acute promyelocytic leukemia undergoing consolidation therapy. In: EHA Meeting. 2019. Available from: https://library.ehaweb.org/eha/2019/24th/266645/harry.j.iland.allg.apml5.a.comparative.bioavailability.study.of.encapsulated.html.
Ravandi F, Koumenis I, Johri A, Tallman M, Roboz GJ, Strickland S, et al. Oral arsenic trioxide ORH-2014 pharmacokinetic and safety profile in patients with advanced hematologic disorders. Haematologica 2020;105;1567–74.
Petti MC, Avvisati G, Amadori S, Baccarani M, Guarini AR, Papa G, et al. Acute promyelocytic leukemia: clinical aspects and results of treatment in 62 patients. Haematologica 1987;72;151–5.
Sanz MA, Jarque I, Martín G, Lorenzo I, Martínez J, Rafecas J, et al. Acute promyelocytic leukemia. Therapy results and prognostic factors. Cancer 1988;61;7–13.
Rodeghiero F, Avvisati G, Castaman G, Barbui T, Mandelli F. Early deaths and anti-hemorrhagic treatments in acute promyelocytic leukemia. A GIMEMA retrospective study in 268 consecutive patients. Blood 1990;75;2112–17.
Fenaux P, Pollet JP, Vandenbossche-Simon L, Morel P, Zandecki M, Jouet JP, et al. Treatment of acute promyelocytic leukemia: a report of 70 cases. Leuk Lymphoma 1991;4;239–48.
Avvisati G, Mandelli F, Petti MC, Vegna ML, Spadea A, Liso V, et al. Idarubicin (4-demethoxydaunorubicin) as single agent for remission induction of previously untreated acute promyelocytic leukemia: a pilot study of the Italian cooperative group GIMEMA. Eur J Haematol 1990;44;257–60.
Ruggero D, Baccarani M, Guarini A, Gugliotta L, Gobbi M, Ricci P, et al. Acute promyelocytic leukemia: results of therapy and analysis of 13 cases. Acta Haematol 1977;58;108–19.
Daly PA, Schiffer CA, Wiernik PH. Acute promyelocytic leukemia—clinical management of 15 patients. Am J Hematol 1980;8;347–59.
Arlin Z, Kempin S, Mertelsmann R, Gee T, Higgins C, Jhanwar S, et al. Primary therapy of acute promyelocytic leukemia: results of amsacrine- and daunorubicin-based therapy. Blood 1984;63;211–12.
Cordonnier C, Vernant JP, Brun B, Heilmann MG, Kuentz M, Bierling P, et al. Acute promyelocytic leukemia in 57 previously untreated patients. Cancer 1985;55;18–25.
Goldberg MA, Ginsburg D, Mayer RJ, Stone RM, Maguire M, Rosenthal DS, et al. Is heparin administration necessary during induction chemotherapy for patients with acute promyelocytic leukemia?. Blood 1987;69;187–91.
Hoyle CF, Swirsky DM, Freedman L, Hayhoe FGJ. Beneficial effect of heparin in the management of patients with APL. Br J Haematol 1988;68;283–9.
Cunningham I, Gee TS, Reich LM, Kempin SJ, Naval AN, Clarkson BD. Acute promyelocytic leukemia: treatment results during a decade at Memorial Hospital. Blood 1989;73;1116–22.
Thomas X, Archimbaud E, Treille-Ritouet D, Fiere D. Prognostic factors in acute promyelocytic leukemia: a retrospective study of 67 cases. Leuk Lymphoma 1991;4;249–56.
Fenaux P, Tertian G, Castaigne S, Tilly H, Leverger G, Guy H, et al. A randomized trial of amsacrine and rubidazone in 39 patients with acute promyelocytic leukemia. J Clin Oncol 1991;9;1556–61.
Head DR, Kopecky KJ, Willman C, Appelbaum FR. Treatment outcome with chemotherapy in acute promyelocytic leukemia: the Southwest Oncology Group (SWOG) experience. Leukemia 1994;8;S38–S41.
Willemze R, Suciu S, Mandelli F, de Witte T, Cadiou M, Castoldi GL, et al. Treatment of patients with acute promyelocytic leukemia. The EORTC-LCG experience. EORTC Leukemia Cooperative Group. Leukemia 1994;8;S48–S55.
Author information
Authors and Affiliations
Corresponding author
Additional information
Peer review under responsibility of the International Academy for Clinical Hematology
Rights and permissions
This is an open access article distributed under the CC BY-NC 4.0 license (http://creativecommons.org/licenses/by-nc/4.0/).
About this article
Cite this article
Sanz, M.A., Barragán, E. History of Acute Promyelocytic Leukemia. Clin Hematol Int 3, 142–152 (2021). https://doi.org/10.2991/chi.k.210703.001
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.2991/chi.k.210703.001